Equities research analysts forecast that Evergy (NYSE:EVRG) will announce $1.72 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Evergy's earnings. Evergy reported earnings per share of $1.57 during the same quarter last year, which would suggest a positive year-over-year growth rate of 9.6%. The firm is scheduled to announce its next earnings results on Wednesday, November 4th.
On average, analysts expect that Evergy will report full year earnings of $3.00 per share for the current fiscal year. For the next year, analysts anticipate that the company will post earnings of $3.25 per share, with EPS estimates ranging from $3.20 to $3.29. Zacks' earnings per share averages are an average based on a survey of analysts that follow Evergy.
Evergy (NYSE:EVRG) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.68 EPS for the quarter, meeting the Thomson Reuters' consensus estimate of $0.68. Evergy had a net margin of 12.64% and a return on equity of 8.09%. The business had revenue of $1.18 billion during the quarter, compared to analyst estimates of $1.22 billion. During the same quarter last year, the firm posted $0.58 earnings per share.
EVRG has been the subject of a number of recent research reports. Goldman Sachs Group reiterated a "neutral" rating and issued a $58.00 price target on shares of Evergy in a research note on Tuesday, September 1st. Wolfe Research downgraded shares of Evergy from an "outperform" rating to a "peer perform" rating and set a $65.00 price target for the company. in a research note on Monday, August 3rd. Wells Fargo & Company raised shares of Evergy from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $58.00 to $60.00 in a report on Thursday. Finally, ValuEngine cut shares of Evergy from a "hold" rating to a "sell" rating in a report on Thursday, July 2nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of "Buy" and a consensus target price of $66.90.
Evergy stock traded up $0.50 during trading on Friday, reaching $54.92. The stock had a trading volume of 1,698,136 shares, compared to its average volume of 2,408,301. Evergy has a 52-week low of $42.01 and a 52-week high of $76.57. The business has a 50 day moving average price of $51.96 and a 200 day moving average price of $57.27. The company has a quick ratio of 0.61, a current ratio of 0.86 and a debt-to-equity ratio of 1.09. The stock has a market cap of $12.46 billion, a PE ratio of 20.04, a P/E/G ratio of 2.78 and a beta of 0.41.
The company also recently disclosed a quarterly dividend, which was paid on Monday, September 21st. Investors of record on Thursday, August 20th were given a $0.505 dividend. The ex-dividend date was Wednesday, August 19th. This represents a $2.02 dividend on an annualized basis and a yield of 3.68%. Evergy's dividend payout ratio (DPR) is 69.90%.
Several hedge funds and other institutional investors have recently modified their holdings of EVRG. Caisse DE Depot ET Placement DU Quebec boosted its position in shares of Evergy by 230.2% during the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 14,200 shares of the company's stock worth $782,000 after purchasing an additional 9,900 shares in the last quarter. Thrivent Financial for Lutherans boosted its position in shares of Evergy by 36.6% during the 1st quarter. Thrivent Financial for Lutherans now owns 14,188 shares of the company's stock worth $781,000 after purchasing an additional 3,800 shares in the last quarter. Loomis Sayles & Co. L P boosted its position in shares of Evergy by 43.8% during the 1st quarter. Loomis Sayles & Co. L P now owns 12,921 shares of the company's stock worth $712,000 after purchasing an additional 3,933 shares in the last quarter. Two Sigma Advisers LP purchased a new stake in shares of Evergy during the 1st quarter worth $3,008,000. Finally, Two Sigma Investments LP boosted its position in shares of Evergy by 561.0% during the 1st quarter. Two Sigma Investments LP now owns 63,954 shares of the company's stock worth $3,521,000 after purchasing an additional 54,278 shares in the last quarter. Institutional investors own 81.34% of the company's stock.
Westar Energy, Inc engages in the generation, transmission and distribution of electricity in Kansas. It provides electricity to residential, commercial, and industrial customers in the cities of Topeka, Lawrence, Manhattan, Salina, and Hutchinson. The company was founded in 1924 and is headquartered in Topeka, KS.
Featured Article: P/E Growth (PEG)
Get a free copy of the Zacks research report on Evergy (EVRG)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Great Biotech Stocks That Don’t Depend on a Coronavirus Cure
Biotech stocks are some of the most volatile for investors to include in their portfolio. And that volatility can be hard to predict. Biotech companies don’t have a firm correlation with the overall economy. And what can add to the challenge is that many of these companies are small-cap companies that are not well-known names.
These small biotech stocks may shoot higher based on a vaccine or drug candidate that gets national attention. But these small-cap stock also reflect the adage of letting the buyer beware. Because the stark reality for many investors is that the vast majority of these treatments never make it past clinical trials. And that means that a stock that goes up rapidly can move down just as fast.
We’re seeing that right now with the multitude of companies that are competing in the race towards a vaccine and/or treatment for Covid-19 and the novel coronavirus that causes the disease. And if you’ve been good at timing the market, you could have made some good money on some of these candidates.
Of course, if you held the stock too long, you could have lost your shirt as well.
That doesn’t mean however that buy and hold investors should avoid the biotech sector altogether. There are still some attractively priced small-cap biotech companies that are working on treatments for a range of conditions that provide them with a large addressable base. And we’ve identified seven of these stocks in this special presentation.
View the "7 Great Biotech Stocks That Don’t Depend on a Coronavirus Cure".